These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38172380)

  • 21. [Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
    Gaillard N; Fabro-Perray P; Faillie JL; Le Bayon A; Castelnovo G; Dupeyron A; Froger J; Pelissier J; Labauge P
    Rev Neurol (Paris); 2007 Jan; 163(1):72-81. PubMed ID: 17304175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of relapse-associated worsening to overall disability accrual in patients with relapsing-onset multiple sclerosis: A mediation analysis.
    Chen B; Ji SQ; Shen F; Tian DS; Bu BT
    Mult Scler Relat Disord; 2022 Mar; 59():103555. PubMed ID: 35093839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics of patients with late-onset multiple sclerosis.
    Kis B; Rumberg B; Berlit P
    J Neurol; 2008 May; 255(5):697-702. PubMed ID: 18283394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
    Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
    Achiron A
    J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS.
    Ahvenjärvi H; Niiranen M; Simula S; Hämäläinen P; Surcel HM; Remes AM; Ryytty M; Krüger J
    Mult Scler Relat Disord; 2023 Sep; 77():104861. PubMed ID: 37442075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of gender on late-onset multiple sclerosis.
    Bove RM; Healy B; Augustine A; Musallam A; Gholipour T; Chitnis T
    Mult Scler; 2012 Oct; 18(10):1472-9. PubMed ID: 22383227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapses add to permanent disability in relapsing multiple sclerosis patients.
    Koch-Henriksen N; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
    Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
    Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late onset multiple sclerosis: concerns in aging patients.
    Lotti CBC; Oliveira ASB; Bichuetti DB; Castro I; Oliveira EML
    Arq Neuropsiquiatr; 2017 Jul; 75(7):451-456. PubMed ID: 28746432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.
    Magon S; Tsagkas C; Gaetano L; Patel R; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Stippich C; Kappos L; Chakravarty MM; Sprenger T
    J Neurol; 2020 May; 267(5):1536-1546. PubMed ID: 32040710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
    Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.